1. Home
  2. MATH vs MAIA Comparison

MATH vs MAIA Comparison

Compare MATH & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Metalpha Technology Holding Limited

MATH

Metalpha Technology Holding Limited

HOLD

Current Price

$1.20

Market Cap

52.1M

Sector

Finance

ML Signal

HOLD

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.53

Market Cap

49.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MATH
MAIA
Founded
2015
2018
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
52.1M
49.3M
IPO Year
2016
2022

Fundamental Metrics

Financial Performance
Metric
MATH
MAIA
Price
$1.20
$1.53
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
50.6K
1.1M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.53
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$3.10
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.10
$0.87
52 Week High
$4.17
$3.19

Technical Indicators

Market Signals
Indicator
MATH
MAIA
Relative Strength Index (RSI) 40.34 38.48
Support Level $1.10 $1.20
Resistance Level $3.16 $1.66
Average True Range (ATR) 0.07 0.16
MACD 0.04 -0.05
Stochastic Oscillator 70.00 13.43

Price Performance

Historical Comparison
MATH
MAIA

About MATH Metalpha Technology Holding Limited

Metalpha Technology Holding Ltd is a digital asset focused wealth management company. The company predominantly generates revenue from the execution of cryptocurrency-related transactions, which includes the issuance of derivative products to over-the-counter (OTC) clients and its proprietary trading activities. It has partnered with a crypto exchange to provide crypto derivative market-making services for its clients, facilitating the trading of crypto derivative products. In addition, the company also engages in providing traditional financial derivative products, and asset management services. It operates in a single segment which is the trading of proprietary digital assets and derivative contracts, and generates majority of its revenue from Hong Kong.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

Share on Social Networks: